All In Biotech

Drug Trial Radar · NCT06975293

STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas

Open-label, Non-randomized, Multi-cohort, Phase 1b/2 Trial Investigating the Safety, Tolerability, and Antitumor Activity of STC-15 (a METTL3 Inhibitor) as a Part of Combination Therapy With Toripalimab in Participants With Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas

Last checked: Nov 19, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

107

Planned (sponsor's estimate)

Start

May 5, 2025

Primary completion

Dec 29, 2027

Study completion Jun 29, 2028

Sponsor

Lead sponsor
STORM Therapeutics LTDIndustry
Sponsor type
Industry
Collaborators
Coherus Oncology, Inc.
First posted
May 16, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This early phase oncology trial will be conducted at various study centers to investigate the safety, tolerability, and antitumor activity of STC-15 (a METTL3 inhibitor) in combination with toripalimab (anti- programmed cell death 1 \[PD-1\]) in advanced unresectable or metastatic tumors. The Phase 2 Monotherapy part is an open-label, non-randomized, multicenter Simon's 2-stage design that investigates the safety, tolerability, and antitumor activity of STC-15 in participants with selected, relapsed sarcomas subtypes, dedifferentiated (DD) liposarcoma and leiomyosarcoma (uterine and non-uterine).

Conditions

  • Solid Tumor
  • Sarcoma
  • Leiomyosarcoma
  • Dedifferentiated Liposarcoma

Interventions

  • STC-15 in combination with toripalimabDrug

    STC-15 in combination with toripalimab in 21-day cycles

  • STC-15 monotherapyDrug

    STC-15 monotherapy in 21-day cycles

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Combination Cohorts: Safety and tolerability of STC-15 in combination with toripalimabTime frame: 6 months
  2. Phase 2 Monotherapy Cohorts: Antitumor activity of STC-15 monotherapyTime frame: 6 months

Locations

14 sites in 1 country. Site status is shown where the registry gives one.

  • University of California, San Francisco

    San Francisco, California · Recruiting

  • University of Miami-Sylvester Comprehensive Cancer Center

    Miami, Florida · Not yet recruiting

  • Dana Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • START Midwest

    Grand Rapids, Michigan · Recruiting

  • Northwell Health Cancer Institute

    Lake Success, New York · Recruiting

  • Memorial Sloan Kettering Cancer Center

    New York, New York · Not yet recruiting

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio · Recruiting

  • MD Anderson Cancer Center

    Houston, Texas · Not yet recruiting

  • NEXT Houston

    Houston, Texas · Recruiting

  • NEXT Dallas

    Irving, Texas · Recruiting

  • NEXT Oncology

    San Antonio, Texas · Recruiting

  • The START Center

    San Antonio, Texas · Recruiting

  • NEXT Oncology

    Fairfax, Virginia · Recruiting

  • Fred Hutchinson Cancer Center

    Seattle, Washington · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.